Avita Medical
Avita Medical Inc. is a regenerative medicine company specializing in therapeutic skin restoration. Their flagship product, the RECELL System, is FDA-approved for treating thermal burn wounds and full-thickness skin defects. The company leverages patient-derived skin cells to enhance healing and accelerate recovery, positioning itself as a leader in acute wound care solutions.
Short position
Avita Medical (ASX:AVH) has 0.12% of its shares on issue reported as short positions as of 5 Oct 2026, or about 88,026 shares. Over the past 30 days that figure has been broadly flat, and over 90 days it has fallen 0.14 percentage points. Its highest recorded short interest was 10.06% in November 2020. AVH is classified in the Pharmaceuticals, Biotechnology & Life Sciences industry. All figures come from official ASIC short position reports, published with a four trading-day (T+4) delay.
Price & short interest
Toggle series, zoom, and compare · ASIC daily, T+4Avita Medical (AVH) financials
Results, ratios and statements
Latest result
12 months to 30 Jun 2026 (TTM Jun 26) vs TTM Jun 25, figures in USD, the reporting currency
- Revenue
- 75.6Mvs n/a (TTM Jun 25)
- Yahoo Finance, as at 29 Sep 2026
- NPAT
- −43.1Mvs n/a (TTM Jun 25)
- Yahoo Finance, as at 29 Sep 2026
- EPS (diluted)
- −0.29vs −0.39 (TTM Jun 25)
- Yahoo Finance, as at 29 Sep 2026
- Rev YoY
- +11.5%FY
- EPS YoY
- n/aTTM
Key ratios
12 months to 30 Jun 2026 (TTM); balance sheet at 30 Jun 2026; prices to 9 Oct 2026
- Gross margin
- 81.6%
- Operating margin
- −46.6%
- Net margin
- −57.0%
- FCF margin
- −33.5%
- ROE
- n/a
- ROA
- −81.4%
- FCF conversion
- n/a
- Net debt (excl. leases)
- USD 37.5M
- Net debt / EBITDA
- n/a
- Current ratio
- 0.4×
- Interest cover
- −6.5×
- Cash dividends paid / net profit
- n/a
- Market cap
- n/a (listed unit is not one ordinary share)
- P/E
- n/a (listed unit is not one ordinary share)
- P/B
- n/a (listed unit is not one ordinary share)
Ratios use the reporting currency (USD); market cap is in AUD. Source: Yahoo Finance, as at 29 Sep 2026.
Financial statements
Figures in USD, the reporting currency; Yahoo Finance unless marked
| Line item | TTM Jun 26 | FY25 | FY24 | FY23 | FY22 |
|---|---|---|---|---|---|
| Revenue | 75.6M | 71.6M | 64.3M | 50.1M | 34.4M |
| Gross profit | 61.7M | 58.8M | 55.2M | 42.4M | 28.4M |
| Operating income | −35.2M | −42.5M | −56.6M | −42.7M | −27.5M |
| EBITDA | −35.1M | −41.2M | −55.3M | −33.5M | −26.0M |
| EBIT | −37.7M | −43.6M | −56.4M | −34.2M | −26.6M |
| Interest expense | 5.4M | 5.0M | 5.4M | 1.1M | 16.0K |
| Pretax income | −43.1M | −48.6M | −61.8M | −35.3M | −26.6M |
| Tax | 21.0K | 11.0K | 54.0K | 66.0K | 36.0K |
| NPAT | −43.1M | −48.6M | −61.8M | −35.4M | −26.7M |
| Net interest income | −5.4M | −5.0M | −5.4M | −1.1M | −16.0K |
| EPS basic | −0.29 | −0.35 | −0.48 | −0.28 | −0.21 |
| EPS diluted | −0.29 | −0.35 | −0.48 | −0.28 | −0.21 |
| Shares | n/a | 30.6M | 26.4M | 25.7M | 25.2M |
Financial reports
The company's own filings, newest first
- AVITA Medical announces Q2 2026 financial resultsFinancial Report7 Aug 2026via asx_announcements
- Half Yearly ReportHalf Year Results7 Aug 2026via asx_announcements
- AVITA Q2 financial results earnings presentationFinancial Report7 Aug 2026via asx_announcements
- AVITA 10-Q Quarterly Report for Q2 2026Quarterly Report7 Aug 2026via asx_announcements
- AVITA to Announce Second Quarter 2026 Financial ResultsFinancial Report15 Jul 2026via asx_announcements
- AVITA Medical Reports First Quarter 2026 Financial ResultsFinancial Report15 May 2026via asx_announcements
- Financial Results for Quarter Ending 31 March 2026Financial Report15 May 2026via asx_announcements
- AVITA to Announce First Quarter 2026 Financial ResultsFinancial Report24 Apr 2026via asx_announcements
- Appendix 4E and Annual Report (Form 10-K)Annual Results13 Feb 2026via asx_announcements
- AVITA Reports Q4 and Full Year 2025 Financial ResultsFull Year Results13 Feb 2026via asx_announcements
Showing 10 of 110 reports